FDA Approves New Combination Therapy for High-Risk Kidney Cancer

The FDA has granted approval for a new combination treatment, Welireg and Keytruda, for adults with clear cell renal cell carcinoma at high risk of recurrence post-surgery. This marks a significant advancement as the first combination of a PD-1 inhibitor and a HIF-2α inhibitor for this condition. Clinical trials demonstrated a 28% reduction in the risk of disease recurrence, metastasis, or death.